Suppr超能文献

可溶性重组人血栓调节蛋白中主要糖胺聚糖附着位点的鉴定:糖基转移酶对丝氨酸474的竞争对功能的潜在调节作用

Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474.

作者信息

Gerlitz B, Hassell T, Vlahos C J, Parkinson J F, Bang N U, Grinnell B W

机构信息

Department of Cardiovascular Research, Lilly Research Laboratories, Indianapolis, IN 46285.

出版信息

Biochem J. 1993 Oct 1;295 ( Pt 1)(Pt 1):131-40. doi: 10.1042/bj2950131.

Abstract

Thrombomodulin (TM) is an endothelial cell thrombin receptor that converts thrombin from a procoagulant to an anticoagulant enzyme. It has previously been shown that TM is expressed in both a high-M(r) form containing chondroitin sulphate and a low-M(r) form lacking this modification. Site-directed mutagenesis of a soluble human TM derivative (TMD1) was employed to determine the attachment site(s) of this functionally important oligosaccharide on the core protein. Although there are four serine residues within the Ser/Thr-rich domain of TMD1 that might support glycosaminoglycan assembly, our analysis demonstrates that the primary site of attachment is at Ser474, and evidence is presented for low levels of attachment at Ser472. It was possible to improve the overall degree of attachment by mutating Ser472 to glutamic acid (so as to conform Ser474 to the xylosyltransferase acceptor consensus acidic-Gly-Ser-Gly-acidic); however, a significant proportion (approx. 35%) of the total TM still lacked a glycosaminoglycan moiety. Mutants that possess a substitution for Ser474 show an increased mobility of their low-M(r) form on SDS/PAGE compared with native TMD1. Isolation and sequencing of a C-terminal peptide demonstrated that this serine is modified in the low-M(r) form of native TMD1. An apparent 'acceptor consensus overlap' at Ser474 suggests that the mechanism behind the glycosaminoglycan split of TM may involve a competition for substrate between xylosyltransferase and N-acetylgalactosaminyltransferase.

摘要

血栓调节蛋白(TM)是一种内皮细胞凝血酶受体,可将凝血酶从促凝酶转化为抗凝酶。先前已经表明,TM以两种形式表达,一种是含有硫酸软骨素的高分子量(M(r))形式,另一种是缺乏这种修饰的低分子量形式。采用定点诱变可溶性人TM衍生物(TMD1)来确定这种功能重要的寡糖在核心蛋白上的附着位点。虽然TMD1富含丝氨酸/苏氨酸结构域内有四个丝氨酸残基可能支持糖胺聚糖组装,但我们的分析表明主要附着位点在Ser474,并且有证据表明Ser472处存在低水平的附着。通过将Ser472突变为谷氨酸(以使Ser474符合木糖基转移酶受体共有序列酸性-甘氨酸-丝氨酸-甘氨酸-酸性),有可能提高整体附着程度;然而全部TM中仍有很大一部分(约35%)缺乏糖胺聚糖部分。与天然TMD1相比,在Ser474处有替代的突变体在SDS/PAGE上其低分子量形式的迁移率增加。对C末端肽的分离和测序表明,该丝氨酸在天然TMD1的低分子量形式中被修饰。Ser474处明显的“受体共有序列重叠”表明,TM糖胺聚糖分裂背后的机制可能涉及木糖基转移酶和N-乙酰半乳糖胺基转移酶之间对底物的竞争。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce90/1134829/ab5850cf06f5/biochemj00102-0138-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验